Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

AI Briefing

• – Sarepta Therapeutics receives FDA meeting request for AMONDYS 45 and VYONDYS 53
• – Sarepta Therapeutics leads in precision genetic medicine for rare diseases
• – U.S. Food and Drug Administration (FDA) reviews supplemental new drug applications (sNDA) for AMONDYS 45 and VYONDYS 53